Collegium Pharma (NASDAQ: COLL) reported Q2 EPS of $1.92, $0.20 better than the analyst estimate of $1.72. Revenue for the quarter came in at $199.87 million versus the consensus estimate of $201.41 million.

FY2026 Outlook-

Revenue between $825 million to $855 million versus the consensus $869.9 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.